Shasha Zhu

Shasha Zhu

Auto-generated profile, based on publicly available information

Shasha Zhu

Department of Obstetrics and Gynecology Engineering Research Center of Biopreservation and Artificial Organs the First Affiliated Hospital of Anhui Medical University NHC Key Laboratory of Study on Abnormal Gametes and Reproductive Tract (Anhui Medical University) Ministry of Education Hefei Anhui China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2023 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
MZMingxu Zhao
Mingxu Zhao
SZShasha Zhu
Shasha Zhu
DZDing Zhang
Ding Zhang
CZChang Zhou
Chang Zhou
ZYZhilai Yang
Zhilai Yang
JZJiqian Zhang
Jiqian Zhang
Postoperative pain (POP) can promote tumor recurrence and reduce the cancer patient's quality of life. However, POP management has always been separated from tumor treatment in clinical practice, and traditional postoperative analgesia using opioids is still unsatisfactory for patients, which is not conducive to tumor treatment. Here, ropivacaine, a popular amide-type LA, was introduced into a Pluronic F127 hydrogel. Postoperative analgesia with ropivacaine-loaded hydrogels reduced the incidence of high-dose ropivacaine-induced convulsions and prolonged pain relief for more than 16 h. More interestingly, ropivacaine-loaded hydrogel was found to upregulate major histocompatibility complex class I (MHC-I) in tumor cells by impairing autophagy. Therefore, a hydrogel co-dopped with ropivacaine and TLR7 agonist imiquimod (PFRM) was rationally synthesized. After postoperative analgesia with PFRM, imiquimod primes tumor-specific CD8+T cells through promoting DCs maturation, and ropivacaine facilitates tumor cells recognition by primed CD8+T cells through upregulating MHC-I. Consequently, postoperative analgesia with PFRM maximumly increases CD8+T cells infiltration into residual tumor tissue and prevents tumor recurrence. Overall, this study for the first time provides an LA-based approach for simultaneous long-lasting postoperative analgesia and prevention of tumor recurrence.

26 February 2019 in Science Signaling
Verified
Journal Article
Closed access
PDF file
SFSicheng Fu
Sicheng Fu
SZShasha Zhu
Shasha Zhu
CTChenxi Tian
Chenxi Tian
SBShiyu Bai
Shiyu Bai
JZJiqian Zhang
Jiqian Zhang
LBLi Bai
Li Bai
Invariant natural killer T (iNKT) cells are innate-like T lymphocytes that express an invariant T cell receptor (TCR), which recognizes glycolipid antigens presented on CD1d molecules. These cells are phenotypically and functionally distinct from conventional T cells. When we characterized the metabolic activity of iNKT cells, consistent with their activated phenotype, we found that they had much less mitochondrial respiratory capacity but increased glycolytic activity in comparison to naïve conventional CD4+ T cells. After TCR engagement, iNKT cells further increased aerobic glycolysis, which was important for the expression of interferon-γ (IFN-γ). Glycolytic metabolism promoted the translocation of hexokinase-II to mitochondria and the activation of mammalian target of rapamycin complex 2 (mTORC2). Inhibiting glycolysis reduced the activity of Akt and PKCθ, which inhibited TCR recycling and accumulation within the immune synapse. Diminished TCR accumulation in the immune synapse reduced the activation of proximal and distal TCR signaling pathways and IFN-γ production in activated iNKT cells. Our studies demonstrate that glycolytic metabolism augments TCR signaling duration and IFN-γ production in iNKT cells by increasing TCR recycling.

26 April 2024 in Acta Biomaterialia
Verified
Journal Article
Closed access
MZMingxu Zhao
Mingxu Zhao
MZMengni Zhou
Mengni Zhou
PLPengcheng Lu
Pengcheng Lu
YWYing Wang
Ying Wang
RZRong Zeng
Rong Zeng
JZJiqian Zhang
Jiqian Zhang

2 December 2023 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
XQXin Qing
Xin Qing
RDRenbin Dou
Renbin Dou
PWPeng Wang
Peng Wang
MZMengni Zhou
Mengni Zhou
CCChenchen Cao
Chenchen Cao
XLXuesheng Liu
Xuesheng Liu
Chemotherapy can cause severe pain for patients, but there are currently no satisfactory methods of pain relief. Enhancing the efficacy of chemotherapy to reduce the side effects of high-dose chemotherapeutic drugs remains a major challenge. Moreover, the treatment of chemotherapy-induced peripheral neuropathic pain (CIPNP) is separate from chemotherapy in the clinical setting, causing inconvenience to cancer patients. In view of the many obstacles mentioned above, we developed a strategy to incorporate local anesthetic (LA) into a cisplatin-loaded PF127 hydrogel for painless potentiated chemotherapy. We found that multiple administrations of cisplatin-loaded PF127 hydrogels (PFC) evoked severe CIPNP, which correlated with increased pERK-positive neurons in the dorsal root ganglion (DRG). However, incorporating ropivacaine into the PFC relieved PFC-induced CIPNP for more than ten hours and decreased the number of pERK-positive neurons in the DRG. Moreover, incorporating ropivacaine into the PFC for chemotherapy is found to upregulate major histocompatibility complex class I (MHC-I) expression in tumor cells and promote the infiltration of cytotoxic T lymphocytes (CD8+ T cells) in tumors, thereby potentiating chemotherapy efficacy. This study proposes that LA can be used as an immunemodulator to enhance the effectiveness of chemotherapy, providing new ideas for painless cancer treatment.

31 March 2025 in Theranostics
Verified
Journal Article
Open access
PDF file
MZMengni Zhou
Mengni Zhou
YWYing Wang
Ying Wang
CLCaihua Li
Caihua Li
JLJinfu Li
Jinfu Li
RDRenbin Dou
Renbin Dou
SZShasha Zhu
Shasha Zhu
Rationale: Endometriosis, characterized by the presence of ectopic endometrial-like tissue, is a common chronic inflammatory disorder in gynecology. However, current treatments, including surgery and hormone therapy, often yield suboptimal outcomes and significant adverse effects. The lack of a drug delivery system specifically targeting ectopic lesions remains a major barrier to the development of more effective treatments.

26 September 2023 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
HZHuimin Zhang
Huimin Zhang
SCSanwei Chen
Sanwei Chen
YZYuwei Zhang
Yuwei Zhang
CTChenxi Tian
Chenxi Tian
JPJun Pan
Jun Pan
LBLi Bai
Li Bai
Dysfunction of intratumoral invariant natural killer T (iNKT) cells hinders their antitumor efficacy, but the underlying mechanisms and the relationship with endogenous antigen priming remain to be explored. Here, we report that antigen priming leads to metabolic reprogramming and epigenetic remodeling, which causes functional reprogramming in iNKT cells, characterized by limited cytokine responses upon restimulation but constitutive high cytotoxicity. Mechanistically, impaired oxidative phosphorylation (OXPHOS) in antigen-primed iNKT cells inhibited T-cell receptor signaling, as well as elevation of glycolysis, upon restimulation via reducing mTORC1 activation, and thus led to impaired cytokine production. However, the metabolic reprogramming in antigen-primed iNKT cells was uncoupled with their enhanced cytotoxicity; instead, epigenetic remodeling explained their high expression of granzymes. Notably, intratumoral iNKT cells shared similar metabolic reprogramming and functional reprogramming with antigen-primed iNKT cells due to endogenous antigen priming in tumors, and thus recovery of OXPHOS in intratumoral iNKT cells by ZLN005 successfully enhanced their antitumor responses. Our study deciphers the influences of antigen priming-induced metabolic reprogramming and epigenetic remodeling on functionality of intratumoral iNKT cells, and proposes a way to enhance efficacy of iNKT cell-based antitumor immunotherapy by targeting cellular metabolism.